Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23693972 | 1.00 | LTA4H (0.55) | LTA4HABCB1CHRNB4CHRNA3HTR1A | |
| SCHEMBL21094976 | 1.00 | LTA4H (0.55) | LTA4HABCB1CHRNB4CHRNA3HTR1A | |
| SCHEMBL21095169 | 0.88 | ABCB1 (0.59) | ABCB1HTR1ADRD2CYP2D6HTR2A | |
| SCHEMBL21095600 | 0.88 | ABCB1 (0.59) | ABCB1HTR1ADRD2CYP2D6HTR2A | |
| SCHEMBL21095171 | 0.88 | ABCB1 (0.59) | ABCB1HTR1ADRD2CYP2D6HTR2A | |
| SCHEMBL21094972 | 0.81 | ADRA2C (0.67) | ABCB1HTR1AADRA2CHTR2A | |
| SCHEMBL21094973 | 0.81 | ADRA2C (0.67) | ABCB1HTR1AADRA2CHTR2A | |
| SCHEMBL21094977 | 0.81 | ADRA2C (0.67) | ABCB1HTR1AADRA2CHTR2A | |
| SCHEMBL21094967 | 0.80 | ABCB1 (0.54) | ABCB1HTR1ADRD2ABCG2KCNH2 | |
| SCHEMBL5558417 | 0.76 | LTA4H (0.48) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | LTA4H 502/4885ABCB1 50/4885CHRNB4 364/4885 |
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | LTA4H 865/4885ABCB1 98/4885CHRNB4 2632/4885 |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | LTA4H 1789/4885ABCB1 105/4885CHRNB4 3349/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | LTA4H 629/4885ABCB1 59/4885CHRNB4 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.